Document:

Exhibit
4.13

 

REGISTRATION
RIGHTS AGREEMENT

 

This Registration
Rights Agreement (the “Agreement”) is made and entered into as of this
14th day of April, 2004 by and among IMCOR Pharmaceutical Co., a Nevada
corporation (the “Company”), and the “Purchasers” named in that certain
Securities Purchase Agreement, of even date herewith, by and among the Company
and the Purchasers (the “Purchase Agreement”).

 

The parties hereby
agree as follows:

 

1.             Certain Definitions.  Capitalized terms used and not otherwise defined herein that are
defined in the Purchase Agreement will have the meanings given such terms in
the Purchase Agreement.  As used in this
Agreement, the following terms shall have the following meanings:

 

“Affiliate”
means, with respect to any person, any other person which directly or
indirectly controls, is controlled by, or is under common control with, such
person.

 

“Business Day”
means a day, other than a Saturday or Sunday, on which banks in New York City
are open for the general transaction of business.

 

 “Closing Price” as of any date means
(a) the closing bid price of one share of Common Stock as reported on The
Nasdaq SmallCap Market (“Nasdaq”) or other national securites exchange
or OTC bulletin board on which the Company’s shares may be quoted or listed on
such date, (b) if no closing bid price is available, the average of the high
bid and the low asked price quoted on Nasdaq on such date, or (c) if the shares
of Common Stock are not then quoted on Nasdaq, the value of one share of Common
Stock on such date as shall be determined in good faith by the Board of
Directors of the Company and the Purchasers, provided, that if the Board
of Directors of the Company and the Purchasers are unable to agree upon the
value of a share of Common Stock pursuant to this subpart (c), the Company and
the Purchasers shall jointly select an appraiser who is experienced in such
matters to determine the Closing Price. 
The decision of such appraiser shall be final and conclusive, and the
cost of such appraiser shall be borne one-half by the Company and one-half by
the Purchasers.

 

“Common Stock”
shall mean the Company’s common stock, par value $0.001 per share.

 

“Holder” or
“Holders” shall mean the holder or holders, as the case may be, from
time to time of Registrable Securities.

 

“Prospectus”
shall mean the prospectus included in any Registration Statement, as amended or
supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by such Registration
Statement and by all other amendments and supplements to the prospectus,
including post-effective amendments and all material incorporated by reference
in such prospectus.

 

“Purchasers”
shall mean the Purchasers identified in the Purchase Agreement and any
Affiliate or permitted transferee of any Purchaser who is a subsequent Holder.

 

“Register,”
“registered” and “registration” refer to a registration made by
preparing and filing a Registration Statement or similar document in compliance
with the 1933 Act, and the declaration or ordering of effectiveness of such
Registration Statement or document.

 

 

“Registrable
Securities” shall mean the shares of Common Stock issued or issuable (i) to
the Purchasers pursuant to the Purchase Agreement, (ii) upon exercise of the
Warrants issued or issuable to the Purchasers pursuant to the Purchase
Agreement, and (iii) upon exercise of compensation warrants issued or issuable
to the placement agents identified in the Disclosure Schedule to the Purchase
Agreement, and any other securities issued or issuable with respect to or in
exchange for Registrable Securities; provided, that, a security
shall cease to be a Registrable Security upon (A) sale pursuant to a
Registration Statement or Rule 144 under the 1933 Act, or (B) such security
becoming eligible for sale by the Holder pursuant to Rule 144(k).

 

“Registration
Statement” shall mean any registration statement of the Company filed under
the 1933 Act that covers the resale of the Registrable Securities pursuant to
the provisions of this Agreement, amendments and supplements to such
Registration Statement, including post-effective amendments, all exhibits and
all material incorporated by reference in such Registration Statement.

 

“SEC” means
the U.S. Securities and Exchange Commission.

 

“Warrants”
means those warrants issued or issuable pursuant to the terms and conditions of
those certain Warrant Agreements dated even date with the Purchase Agreement
entered into pursuant to the Purchase Agreement.

 

“1933 Act”
means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

 

2.             Registration.

 

(a)           Registration Statements.  Not later than the first to occur of (i) the
30th day following the Second Closing and (ii) the 15th day
following termination of the obligations to complete the Second Closing in
accordance with the Purchase Agreement, the Company shall prepare and file with the SEC a
Registration Statement on Form S-1 covering the resale of all Registrable
Securities.  The Registration Statement
shall contain (except if otherwise required pursuant to written comments
received from the SEC upon a review of such Registration Statement) the “Plan
of Distribution” attached hereto as Annex A.  Such Registration Statement also shall cover, to the
extent allowable under the 1933 Act and the rules promulgated thereunder
(including Rule 416), such indeterminate number of additional shares of Common
Stock resulting from stock splits, stock dividends or similar transactions with
respect to the Registrable Securities. 
The “Selling Stockholders” and
“Plan of Distribution” sections of the Registration Statement (and each
amendment or supplement thereto, and each request for acceleration of
effectiveness thereof) and any risk factor contained in such document that
addresses specifically this transaction or the Selling Stockholders, shall be
provided in accordance with Section 3(c) to the Holders prior to its
filing or other submission.  Promptly
following any date on which the Company becomes eligible to use a registration
statement on Form S-3 to register Registrable Securities for resale, but in no
event more than 20 days after such date, the Company shall file a Registration
Statement on Form S-3 covering the Registrable Securities (or a post-effective
amendment on Form S-3 to the then effective Registration Statement) and shall
cause such Registration Statement to be declared effective as soon as possible
thereafter, but in any event by the 90th day following the date on
which the Company becomes eligible to utilize Form S-3 for the registration of
the resale of its securities by selling stockholders.

 

(b)           Expenses.  The Company will pay all expenses associated
with each registration hereunder, including filing and printing fees, counsel
and accounting fees and expenses, costs associated

 

2

 

with clearing the
Registrable Securities for sale under applicable state securities laws, listing
fees and the Purchasers’ reasonable expenses in connection with the
registration, but excluding discounts, commissions, fees of Holder’ counsel,
and fees of underwriters, selling brokers, dealer managers or similar
securities industry professionals with respect to the Registrable Securities
being sold.

 

(c)           Effectiveness.

 

(i)            The Company shall use its reasonable
best efforts to have the Registration Statement declared effective as soon as
possible, but in any event by the “Effectiveness Date” defined below for such
Registration Statement.  “Effectiveness
Date” for the initial Registration Statement required hereunder means the
first to occur of (a) the 60th day following the Second Closing (or 90th
day after the Second Closing if the filed Registration Statement is reviewed
and commented upon by the SEC), (b) the 60th day following
termination of the obligations to complete the Second Closing in accordance
with the Purchase Agreement (or 90th day after such event if the
filed Registration Statement is reviewed and commented upon by the SEC), and (c) the fifth Business Day following the
date on which the Company is notified by the SEC that such Registration
Statement will not be reviewed or is no longer subject to further review and
comments.  If a Registration
Statement covering all Registrable Securities is not declared effective by the
SEC by the Effectiveness Date, then the
Company will, in addition to all other rights of the Holders hereunder and under
applicable law, as partial liquidated damages and not as a penalty, make
payments to each Purchaser in accordance with Section 2(e) hereof.

 

(ii)           For not more than twenty-five (25)
consecutive days or for a total of not more than forty (40) days in any twelve
(12) month period, the Company may delay the disclosure of material non-public
information concerning the Company, by suspending the use of any Prospectus
included in any registration contemplated by this Section containing such
information, the disclosure of which at the time would be, in the good faith
opinion of the Company, materially detrimental to the Company (an “Allowed
Delay”); provided, that the Company shall promptly (a) notify the
Holders in writing of the existence of (but in no event, without the prior
written consent of a Purchaser, shall the Company disclose to such Purchaser
any of the facts or circumstances regarding) material non-public information
giving rise to an Allowed Delay, and (b) advise the Holders in writing to cease
all sales under the Registration Statement until the end of the Allowed
Delay.  Liquidated damages set forth in
Section 2(e) will be due and payable notwithstanding any Allowed Delays
hereunder.

 

(d)           Underwritten
Offering.  If any offering pursuant
to a Registration Statement pursuant to Section 2(a) hereof involves an
underwritten offering, the Company shall have the right to select an investment
banker and manager to administer the offering, which investment banker or
manager shall be reasonably satisfactory to the Holders holding a majority of
the Registrable Securities.

 

(e)           Liquidated
Damages.  If: (i) a Registration
Statement is not timely filed in accordance with Section 2(a) hereof (if the
Company files a Registration Statement without affording the Holders the
opportunity to review and comment on the same as required by Section 3(c)
hereof, the Company shall not be deemed to have satisfied this clause (i)), or
(ii) a Registration Statement is not timely declared effective by the SEC in
accordance with Section 2(c) hereof, or (iii) after the date upon which the
Registration Statement is declared effective by the SEC, without regard for the
reason thereunder or efforts therefore and without regard to any Allowed
Delays, such Registration Statement ceases for any reason to be effective and
available to the Holders as to all Registrable Securities to which it is
required to cover at any time prior to the time when such Registrable
Securities have ceased to be “Registrable Securities” in accordance with the definition
of Registrable Securities for more than an aggregate of 20 Business Days (which
need not be consecutive) (any such failure or breach being referred to as an “Event,”
and for purposes of clauses (i) or (ii) the date on which such Event occurs, or
for purposes of clause (iii) the date which such 20 Business Day-period is
exceeded, being referred to as “Event Date”),

 

3

 

then, in addition to any other rights available to the Holders under
this Agreement or under applicable law, on each such Event Date, and each
monthly anniversary thereof, the Company shall issue to each Holder an amount
in freely tradeable shares of validly issued, fully paid and non-assessable
shares of Common Stock (which shall become Registrable Shares), as liquidated
damages and not as a penalty, equal to 2% of the aggregate investment amount
paid by such Holder pursuant to the Purchase Agreement (valued at the Closing
Price).  The partial liquidated damages
pursuant to this Section shall apply on a pro rata basis for any portion of a
month prior to the cure of an Event, other with respect to the first Event Date
(for which the entire partial liquidated damages for that month will be due in
full on the initial Event Date).

 

3.             Company Obligations.  The Company will effect the registration of
the Registrable Securities in accordance with the terms hereof, and pursuant
thereto the Company will, as expeditiously as possible:

 

(a)           use its reasonable best efforts to
cause such Registration Statement to become effective and to remain
continuously effective until such time as the Registrable Securities covered
thereby are no longer “Registrable Securities” under the definition thereof;

 

(b)           prepare and file with the SEC such
amendments and post-effective amendments to the Registration Statement and the
Prospectus as may be necessary to keep the Registration Statement effective for
the period specified in Section 3(a) hereof and to comply with the
provisions of the 1933 Act and the 1934 Act with respect to the distribution of
all of the Registrable Securities covered thereby;

 

(c)           provide copies to and permit each
Holder to review the
“Selling Stockholders” and “Plan of Distribution” sections of each Registration
Statement and any risk factor that addresses specifically this transaction or
the Selling Stockholders under the Registration Statement and all amendments
and supplements thereto, no fewer than five (5) Business Days prior to
their filing with the SEC and not, without the consent of such Holder, file any
Registration Statement that contains disclosure regarding a Holder that differs
in any material respect with the disclosure set forth in the Selling Holder
Questionnaire (as hereinafter defined) provided by such Holder for use in such
Registration Statement;

 

(d)           furnish to the Holders (i) promptly
after the same is prepared and publicly distributed, filed with the SEC, or
received by the Company (but not later than two (2) Business Days after the
filing date, receipt date or sending date, as the case may be) one (1) copy of
any Registration Statement and any amendment thereto, each preliminary
prospectus and Prospectus and each amendment or supplement thereto, and each
letter written by or on behalf of the Company to the SEC or the staff of the
SEC, and each item of correspondence from the SEC or the staff of the SEC, in
each case relating to such Registration Statement (other than any portion of
any thereof which contains information for which the Company has sought
confidential treatment or believes might constitute material and non-public
information concerning the Company), and (ii) such number of copies of a
Prospectus, including a preliminary prospectus, and all amendments and
supplements thereto and such other documents as each Holder may reasonably
request in order to facilitate the disposition of the Registrable Securities
owned by such Holder that are covered by the related Registration Statement;

 

(e)           in the event of an underwritten
offering hereunder wherein the Company selects an underwriter, the Company
shall enter into and perform its reasonable obligations under an underwriting
agreement, in usual and customary form, including, without limitation,
customary indemnification and contribution obligations, with the underwriter of
such offering;

 

(f)            if required by the underwriter, or
if any Holder is described in the Registration Statement as an underwriter, the
Company shall furnish, on the effective date of the Registration Statement
(except with respect to clause (i) below) and on the date that Registrable
Securities are delivered to an

 

4

 

underwriter, if
any, for sale in connection with the Registration Statement (including any
Holder deemed to be an underwriter), (i) (A) in the case of an underwritten
offering, an opinion, dated as of the closing date of the sale of Registrable
Securities to the underwriters, from legal counsel representing the Company for
purposes of such Registration Statement, in form, scope and substance as is customarily
given in an underwritten public offering, addressed to the underwriters and the
Holders participating in such underwritten offering or (B) in the case of an
“at the market” offering, an opinion, dated as of or promptly after the
effective date of the Registration Statement to the Holders, from legal counsel
representing the Company for purposes of such Registration Statement, in form,
scope and substance as is customarily given in a public offering, addressed to
the Holders, and (ii) a letter, dated as of the effective date of such
Registration Statement and confirmed as of the applicable dates described
above, from the Company’s independent certified public accountants in form and
substance as is customarily given by independent certified public accountants
to underwriters in an underwritten public offering, addressed to the
underwriters (including any Holder deemed to be an underwriter);

 

(g)           use its reasonable best efforts to
(i) prevent the issuance of any stop order or other suspension of effectiveness
and, (ii) if such order is issued, obtain the withdrawal of any such order at
the earliest possible moment;

 

(h)           prior to any public offering of
Registrable Securities, use its reasonable best efforts to register or qualify
or cooperate with the Holders and their counsel in connection with the
registration or qualification of such Registrable Securities for offer and sale
under the securities or blue sky laws of such jurisdictions requested by the
Holders and do any and all other commercially reasonable acts or things
necessary or advisable to enable the distribution in such jurisdictions of the
Registrable Securities covered by the Registration Statement;

 

(i)            use its reasonable best efforts to
cause all Registrable Securities covered by a Registration Statement to be
listed on each securities exchange, interdealer quotation system or other
market on which similar securities issued by the Company are then listed;

 

(j)            immediately notify the Holders, at
any time when a Prospectus relating to Registrable Securities is required to be
delivered under the 1933 Act, upon discovery that, or upon the happening of any
event as a result of which, the Prospectus included in a Registration
Statement, as then in effect, includes an untrue statement of a material fact
or omits to state any material fact required to be stated therein or necessary
to make the statements therein not misleading in light of the circumstances
then existing, and at the request of any such Holder, promptly prepare and
furnish to such Holder a reasonable number of copies of a supplement to or an
amendment of such Prospectus as may be necessary so that, as thereafter
delivered to the Holders of such Registrable Securities, such Prospectus shall
not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein
not misleading in light of the circumstances then existing; and

 

(k)           otherwise comply with all applicable
rules and regulations of the SEC under the 1933 Act and the 1934 Act, use its
reasonable best efforts to take such other actions as may be reasonably
necessary to facilitate the registration of the Registrable Securities
hereunder; and make available to its security holders, as soon as reasonably
practicable, but not later than the Availability Date (as defined below), an
earnings statement covering a period of at least twelve (12) months, beginning
after the effective date of each Registration Statement, which earnings
statement shall satisfy the provisions of Section 11(a) of the 1933 Act (for
the purpose of this section 3(k), “Availability Date” means the
45th day following the end of the fourth fiscal quarter that includes the
effective date of such Registration Statement, except that, if such fourth
fiscal quarter is the last quarter of the Company’s fiscal year, “Availability
Date” means the 90th day after the end of such fourth fiscal quarter).

 

5

 

4.             Obligations of the Holders.

 

(a)           Each Holder agrees to furnish to the Company a completed Questionnaire
in the form attached to this Agreement as Annex B (a “Selling Holder
Questionnaire”).  The Company shall
not be required to include the Registrable Securities of a Holder in a
Registration Statement and shall not be required to pay any partial liquidated
or other damages under Section 2(e) hereof to a Holder who fails to furnish to
the Company a completed Selling Holder Questionnaire at least two (2) Business
Days prior to the date a Registration Statement is required to be filed in
accordance with the requirements set forth in Section 2(a).

 

(b)           Each Holder, by its acceptance of the
Registrable Securities agrees to cooperate with the Company as reasonably
requested by the Company in connection with the preparation and filing of a
Registration Statement hereunder, unless such Holder has notified the Company
in writing of its election to exclude all of its Registrable Securities from
such Registration Statement.

 

(c)           Each Holder covenants and agrees that it will comply with the
prospectus delivery requirements of the 1933 Act as applicable to it in
connection with sales of Registrable Securities pursuant to the Registration
Statement.

 

(d)           Each Holder agrees that, upon receipt
of any notice from the Company of either (A) the commencement of an Allowed
Delay pursuant to Section 2(c)(ii) or (B) the happening of an event
pursuant to Section 3(j) hereof, such Holder will immediately
discontinue disposition of Registrable Securities pursuant to the Registration
Statement covering such Registrable Securities, until the Holder’s receipt of
the copies of the supplemented or amended prospectus filed with the SEC and
declared effective and, if so directed by the Company, the Holder shall deliver
to the Company (at the expense of the Company) or destroy (and deliver to the
Company a certificate of destruction) all copies in the Holder’s possession of
the Prospectus covering the Registrable Securities current at the time of
receipt of such notice.

 

(e)           No Holder may participate in any
third party underwritten registration hereunder unless it (i) agrees to sell
the Registrable Securities on the basis provided in any underwriting
arrangements in usual and customary form entered into by the Company, (ii)
completes and executes all questionnaires, powers of attorney, indemnities,
underwriting agreements and other documents reasonably required under the terms
of such underwriting arrangements, and (iii) agrees to pay its pro rata share
of all underwriting discounts and commissions. 
Notwithstanding the foregoing, no Holder shall be required to make any
representations to such underwriter, other than those with respect to itself
and the Registrable Securities owned by it, including its right to sell the
Registrable Securities, and any indemnification in favor of the underwriter by
the Holders shall be several and not joint and limited in the case of any
Holder, to the proceeds received by such Holder from the sale of its
Registrable Securities.  The scope of
any such indemnification in favor of an underwriter shall be limited to the
same extent as the indemnity
provided in Section 5(a) hereof.

 

5.             Indemnification.

 

(a)           Indemnification by the Company.  The Company will indemnify and hold harmless
each Holder and its officers, directors, members, employees and agents,
successors and assigns, and each other person, if any, who controls such Holder
within the meaning of the 1933 Act, against any losses, claims, damages or
liabilities, joint or several, to which such Holder, officer, director, member,
or controlling person may become subject under the 1933 Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon: (i) any untrue statement or alleged
untrue statement of any material fact contained in any Registration Statement,
any preliminary prospectus

 

6

 

or final
prospectus contained therein, or any amendment or supplement thereof; (ii) any
blue sky application or other document executed by the Company specifically for
that purpose or based upon written information furnished by the Company filed
in any state or other jurisdiction in order to qualify any or all of the
Registrable Securities under the securities laws thereof (any such application,
document or information herein called a “Blue Sky Application”);
(iii) the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading;
(iv) any violation by the Company or its agents of any rule or regulation
promulgated under the 1933 Act applicable to the Company or its agents and
relating to action or inaction required of the Company in connection with such
registration; or (v) any failure to register or qualify the Registrable
Securities included in any such Registration in any state where the Company or
its agents has affirmatively undertaken or agreed in writing that the Company
will undertake such registration or qualification on a Holder’s behalf (the
undertaking of any underwriter chosen by the Company being attributed to the
Company) and will reimburse such Holder, and each such officer, director or
member and each such controlling person for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any
such loss, claim, damage, liability or action; provided, however,
that the Company will not be liable in any such case if and to the extent that
any such loss, claim, damage or liability arises out of or is based upon an
untrue statement or alleged untrue statement or omission or alleged omission so
made in conformity with information furnished by or on behalf of such Holder or
any such controlling person in writing specifically for use in such
Registration Statement or Prospectus.

 

(b)           Indemnification by the Holders.  Each Holder agrees, severally but not
jointly, to indemnify and hold harmless, to the fullest extent permitted by
law, the Company, its directors, officers, employees, stockholders, and
successors and each person who controls the Company (within the meaning of the
1933 Act) against any losses, claims, damages, liabilities and expense
(including reasonable attorney fees) resulting from any untrue statement of a
material fact or any omission of a material fact required to be stated in the
Registration Statement or Prospectus or preliminary prospectus or amendment or
supplement thereto or necessary to make the statements therein not misleading,
to the extent, but only to the extent that such untrue statement or omission is
contained in any information furnished in writing by or on behalf of such
Holder to the Company specifically for inclusion in such Registration Statement
or Prospectus or amendment or supplement thereto.  In no event shall the liability of a Holder be greater in amount
than the dollar amount of the proceeds (net of all expense paid by such Holder
and the amount of any damages such holder has otherwise been required to pay by
reason of such untrue statement or omission) received by such Holder upon the
sale of the Registrable Securities giving rise to such indemnification
obligation.

 

(c)           Conduct of Indemnification
Proceedings.  Any person entitled to
indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim with respect to which it seeks indemnification and (ii)
permit such indemnifying party to assume the defense of such claim with counsel
reasonably satisfactory to the indemnified party; provided that any
person entitled to indemnification hereunder shall have the right to employ
separate counsel and to participate in the defense of such claim, but the fees
and expenses of such separate counsel shall be at the expense of such person
unless (a) the indemnifying party has agreed to pay such fees or expenses, or
(b) the indemnifying party shall have failed to assume the defense of such
claim and employ counsel reasonably satisfactory to such person or (c) in the
reasonable judgment of any such person, based upon written advice of its
counsel, a conflict of interest exists between such person and the indemnifying
party with respect to such claims (in which case, if the person notifies the
indemnifying party in writing that such person elects to employ separate
counsel at the expense of the indemnifying party, the indemnifying party shall
not have the right to assume the defense of such claim on behalf of such
person); and provided, further, that the failure of any
indemnified party to give notice as provided herein shall not relieve the
indemnifying party of its obligations hereunder, except to the extent that such
failure to give notice shall materially adversely

 

7

 

affect the
indemnifying party in the defense of any such claim or litigation.  It is understood that the indemnifying party
shall not, in connection with any proceeding in the same jurisdiction, be
liable for fees or expenses of more than one separate firm of attorneys at any time
for all such indemnified parties.  No
indemnifying party will, except with the consent of the indemnified party,
consent to entry of any judgment or enter into any settlement that does not
include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of a release from all liability in respect
of such claim or litigation.

 

(d)           Contribution.  If for any reason the indemnification
provided for in the preceding paragraphs (a) and (b) is unavailable to an
indemnified party or insufficient to hold it harmless, other than as expressly
specified therein, then the indemnifying party shall contribute to the amount
paid or payable by the indemnified party as a result of such loss, claim,
damage or liability in such proportion as is appropriate to reflect the relative
fault of the indemnified party and the indemnifying party, as well as any other
relevant equitable considerations.  No
person guilty of fraudulent misrepresentation within the meaning of Section
11(f) of the 1933 Act shall be entitled to contribution from any person not
guilty of such fraudulent misrepresentation. 
In no event shall the contribution obligation of a holder of Registrable
Securities be greater in amount than the dollar amount of the proceeds (net of
all expenses paid by such holder and the amount of any damages such holder has
otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission) received by it upon the sale of the
Registrable Securities giving rise to such contribution obligation.

 

6.             Miscellaneous.

 

(a)           Remedies.  In the event of a breach by the Company or
by a Holder of any of their obligations under this Agreement, each Holder or
the Company, as the case may be, in addition to being entitled to exercise all
rights granted by law and under this Agreement, including recovery of damages,
will be entitled to specific performance of its rights under this
Agreement.  The Company and each Holder
agree that monetary damages may not provide adequate compensation for any
losses incurred by reason of a breach by it of any of the provisions of this
Agreement and hereby further agrees that, in the event of any action for
specific performance in respect of such breach, it shall waive the defense that
a remedy at law would be adequate.

 

(b)           No
Piggyback on Registrations.  Except
as and to the extent specified in the Disclosure Schedule to the Purchase
Agreement, neither the Company nor any of its security holders (other than the
Holders in such capacity pursuant hereto) may include securities of the Company
in a Registration Statement hereunder other than the Registrable Securities,
and the Company shall not after the date hereof enter into any agreement
providing any such right to any of its security holders.

 

(c)           Piggy-Back
Registrations.  If at any time while
a Registration Statement is required to be effective hereunder there is not an
effective Registration Statement covering all of the Registrable Securities and
the Company shall determine to prepare and file with the SEC a registration
statement relating to an offering for its own account or the account of others
under the 1933 Act of any of its equity securities, other than with respect to
the Company’s registration to Dr. Gerald Wolf as described in the Disclosure
Schedule or any registration statement on Form S-4 or Form S-8 (each as
promulgated under the 1933 Act) or their then equivalents relating to equity
securities to be issued solely in connection with any acquisition of any entity
or business or equity securities issuable in connection with stock option or
other employee benefit plans, then the Company shall send to each Holder
written notice of such determination and, if within fifteen days after receipt
of such notice, any such Holder shall so request in writing, the Company shall
include in such registration statement all or any part of such Registrable
Securities such holder requests to be registered, subject to customary
underwriter cutbacks applicable to all holders of registration rights.

 

8

 

(e)           Amendments and
Waivers.  The provisions of
this Agreement, including the provisions of this section, may not be amended,
modified or supplemented, and waivers or consents to departures from the
provisions hereof may not be given, unless the same shall be in writing and
signed by the Company and the Holder or Holders (as applicable) of no less than
a majority in interest of the then outstanding Registrable Securities.  Notwithstanding the foregoing, a waiver or
consent to depart from the provisions hereof with respect to a matter that
relates exclusively to the rights of certain Holders and that does not directly
or indirectly affect the rights of other Holders may be given by Holders of at
least a majority of the Registrable Securities to which such waiver or consent
relates.

 

(f)            Notices.  All notices and other communications
provided for or permitted hereunder shall be made as set forth in the Purchase
Agreement or, with respect to a Holder, to such other address as provided in
writing by a Holder to the Company.

 

(g)           Assignments and
Transfers by Holders.  The
provisions of this Agreement shall be binding upon and inure to the benefit of
the Holders and their respective successors and assigns.  A Holder may transfer or assign, in whole or
from time to time in part, to one or more persons its rights hereunder in
connection with the transfer of Registrable Securities by such Holder to such
person, provided that such Holder complies with all laws applicable thereto and
provides written notice of assignment to the Company promptly after such
assignment is effected.

 

(h)           Assignments and
Transfers by the Company.  This
Agreement may not be assigned by the Company (whether by operation of law or
otherwise), provided, however, that the Company must assign its
rights and delegate its duties hereunder to any surviving or successor
corporation in connection with a merger or consolidation of the Company with
another corporation, or a sale, transfer or other disposition of all or
substantially all of the Company’s assets to another corporation.

 

(i)            Benefits of the
Agreement.  The terms and conditions
of this Agreement shall inure to the benefit of and be binding upon the
respective permitted successors and assigns of the parties.  Other than with respect to indemnified
parties hereunder who are not parties to this Agreement, nothing in this
Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement.

 

(j)            Counterparts;
Faxes.  This Agreement may be
executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument.  This Agreement may also be
executed via facsimile, which shall be deemed an original.

 

(k)           Titles and
Subtitles.  The titles and subtitles
used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement.

 

(l)            Severability.  Any provision of this Agreement that is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof but shall be interpreted as if it
were written so as to be enforceable to the maximum extent permitted by
applicable law, and any such prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other
jurisdiction.  To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders
any provisions hereof prohibited or unenforceable in any respect.

 

9

 

(m)          Further Assurances.  The parties hereto shall execute and deliver
all such further instruments and documents and take all such other actions as
may reasonably be required to carry out the transactions contemplated hereby
and to evidence the fulfillment of the agreements herein contained.

 

(n)           Entire Agreement.  This Agreement and the Purchase Agreement
(and the Exhibits and Schedules annexed thereto) are intended by the parties
hereto as a final expression of their agreement and intended to be a complete
and exclusive statement of the agreement and understanding of the parties
hereto in respect of the subject matter contained herein and therein.  This Agreement and the Purchase Agreement
(and the Exhibits and Schedules annexed thereto) supersede all prior agreements
and understandings between the parties with respect to such subject matter.

 

(o)           Governing Law;
Consent to Jurisdiction.  All
questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by and construed and enforced in accordance
with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. 
Each party agrees that all proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement
(whether brought against a party hereto or its respective affiliates, employees
or agents) may be commenced non-exclusively in the state and federal courts
sitting in the City of New York, Borough of Manhattan, (the “New York
Courts”).  Each party hereto
hereby irrevocably submits to the non-exclusive jurisdiction of the New York
Courts for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any proceeding, any claim that
it is not personally subject to the jurisdiction of any New York Court, or that
such proceeding has been commenced in an improper or inconvenient forum.  Each party hereto hereby irrevocably waives
personal service of process and consents to process being served in any such
proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for
notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to
limit in any way any right to serve process in any manner permitted by
law.  Each party hereto hereby
irrevocably waives, to the fullest extent permitted by applicable law, any and
all right to trial by jury in any proceeding arising out of or relating to this
Agreement or the transactions contemplated hereby.  If either party shall commence a proceeding to enforce any
provisions of this Agreement, then the prevailing party in such proceeding
shall be reimbursed by the other party for its attorney’s reasonable fees and
other costs and expenses incurred with the investigation, preparation and
prosecution of such proceeding.

 

(p)           Cumulative
Remedies.  The remedies provided
herein are cumulative and not exclusive of any remedies provided by law.

 

(q)           Independent
Nature of Holders Obligations and Rights. 
The obligations of each Holder hereunder is several and not joint with
the obligations of any other Holder hereunder, and no Holder shall be
responsible in any way for the performance of the obligations of any other
Holder hereunder.  Nothing contained
herein or in any other agreement or document delivered at any closing, and no
action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute
the Holder as a partnership, an association, a joint venture or any other kind
of entity, or create a presumption that the Holder are in any way acting in
concert with respect to such obligations or the transactions contemplated by
this Agreement.  Each Holder shall be
entitled to protect and enforce its rights, including without limitation the
rights arising out of this Agreement, and it shall not be necessary for any
other Holder to be joined as an additional party in any proceeding for such
purpose.  The Company
acknowledges that each of the Purchasers has been provided with the same
Agreement for the purpose of closing a transaction with multiple Purchasers and
not because it was required or requested to do so by any Purchaser.

 

10

 

Signature
pages follow.

 

11

 

IN WITNESS WHEREOF, the parties have executed this
Agreement or caused their duly authorized officers to execute this Agreement as
of the date first above written.

 

	
   

  	
  Company:

  
	
   

  	
   

  
	
   

  	
  IMCOR Pharmaceutical
  Co.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Taffy J. Williams,
  Ph.D.

  
	
   

  	
  Title:

  	
  President and Chief
  Executive Officer

  
					

 

 

IN WITNESS WHEREOF, the parties have executed this
Agreement or caused their duly authorized officers to execute this Agreement as
of the date first above written.

 

 

	
   

  	
  PURCHASER:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  

 

13

 

Annex A

 

Plan of Distribution

 

The Selling Stockholders and any of their pledgees,
donees, transferees, assignees and successors-in-interest may, from time to
time, sell any or all of their shares of Common Stock on any stock exchange,
market or trading facility on which the shares are traded or in private
transactions.  These sales may be at
fixed or negotiated prices.  The Selling
Stockholders may use any one or more of the following methods when selling
shares:

 

•      ordinary brokerage transactions and
transactions in which the broker-dealer solicits Investors;

 

•      block trades in which the broker-dealer
will attempt to sell the shares as agent but may position and resell a portion
of the block as principal to facilitate the transaction;

 

•      purchases by a broker-dealer as principal
and resale by the broker-dealer for its account;

 

•      an exchange distribution in accordance
with the rules of the applicable exchange;

 

•      privately negotiated transactions;

 

•      to cover short sales made after the date
that this Registration Statement is declared effective by the Commission;

 

•      broker-dealers may agree with the Selling
Stockholders to sell a specified number of such shares at a stipulated price
per share;

 

•      a combination of any such methods of sale;
and

 

•      any other method permitted pursuant to
applicable law.

 

The Selling Stockholders may also sell shares under
Rule 144 under the Securities Act, if available, rather than under this
prospectus.

 

Broker-dealers engaged by the Selling Stockholders may
arrange for other brokers-dealers to participate in sales.  Broker-dealers may receive commissions or
discounts from the Selling Stockholders (or, if any broker-dealer acts as agent
for the purchaser of shares, from the purchaser) in amounts to be
negotiated.  The Selling Stockholders do
not expect these commissions and discounts to exceed what is customary in the
types of transactions involved.

 

The Selling Stockholders may from time to time pledge
or grant a security interest in some or all of the Shares owned by them and, if
they default in the performance of their secured obligations, the pledgees or
secured parties may offer and sell shares of Common Stock from time to time
under this prospectus, or under an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act of 1933 amending
the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus.

 

Upon the Company being notified in writing by a
Selling Stockholder that any material arrangement has been entered into with a
broker-dealer for the sale of Common Stock through a block trade, special
offering, exchange distribution or secondary distribution or a purchase by a
broker or dealer, a supplement to this prospectus will be filed, if required,
pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each
such Selling Stockholder and of the participating broker-dealer(s), (ii) the

 

1

 

number of shares
involved, (iii) the price at which such the shares of Common Stock were sold,
(iv)the commissions paid or discounts or concessions allowed to such
broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not
conduct any investigation to verify the information set out or incorporated by
reference in this prospectus, and (vi) other facts material to the
transaction.  In addition, upon the
Company being notified in writing by a Selling Stockholder that a donee or
pledge intends to sell more than 500 shares of Common Stock, a supplement to
this prospectus will be filed if then required in accordance with applicable
securities law.

 

The Selling Stockholders also may transfer the shares
of Common Stock in other circumstances, in which case the transferees, pledgees
or other successors in interest will be the selling beneficial owners for
purposes of this prospectus.

 

The Selling Stockholders and any broker-dealers or
agents that are involved in selling the shares may be deemed to be
“underwriters” within the meaning of the Securities Act in connection with such
sales.  In such event, any commissions received
by such broker-dealers or agents and any profit on the resale of the shares
purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act.  Discounts,
concessions, commissions and similar selling expenses, if any, that can be
attributed to the sale of Securities will be paid by the Selling Stockholder
and/or the purchasers.  Each Selling
Stockholder has represented and warranted to the Company that it acquired the
securities subject to this registration statement in the ordinary course of
such Selling Stockholder’s business and, at the time of its purchase of such
securities such Selling Stockholder had no agreements or understandings,
directly or indirectly, with any person to distribute any such securities.

 

The Company has advised each Selling Stockholder that
it may not use shares registered on this Registration Statement to cover short
sales of Common Stock made prior to the date on which this Registration
Statement shall have been declared effective by the Commission.  If a Selling Stockholder uses this
prospectus for any sale of the Common Stock, it will be subject to the
prospectus delivery requirements of the Securities Act.  The Selling Stockholders will be responsible
to comply with the applicable provisions of the Securities Act and Exchange
Act, and the rules and regulations thereunder promulgated, including, without
limitation, Regulation M, as applicable to such Selling Stockholders in
connection with resales of their respective shares under this Registration
Statement.

 

The Company is required to pay all fees and expenses
incident to the registration of the shares, but the Company will not receive
any proceeds from the sale of the Common Stock.  The Company has agreed to indemnify the Selling Stockholders
against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.  If the
Selling Stockholders use this prospectus for any sale of the Common Stock, they
will be subject to the prospectus delivery requirements of the Securities Act.

 

2

 

Annex B

 

Selling
Securityholder Notice and Questionnaire

 

The undersigned beneficial
owner of common stock (the “Common Stock”), of IMCOR Pharmaceutical
Co. (the “Company”)
understands that the Company has filed or intends to file with the Securities
and Exchange Commission (the “SEC”) a Registration Statement for the
registration and resale of the Registrable Securities, in accordance with the
terms of the Registration Rights Agreement, dated as of April
     , 2004 (the “Registration Rights Agreement”), among the
Company and the Purchasers named therein. 
A copy of the Registration Rights Agreement is available from the
Company upon request at the address set forth below.  All capitalized terms used and not otherwise defined herein shall
have the meanings ascribed thereto in the Registration Rights Agreement.

 

The undersigned hereby
provides the following information to the Company and represents and warrants
that such information is accurate:

 

QUESTIONNAIRE

 

1.             Name.

 

(a)           Full
Legal Name of Selling Securityholder

 

 

 

(b)           Full Legal Name of Registered Holder
(if not the same as (a) above) through which Registrable Securities Listed in
Item 3 below are held:

 

 

 

(c)           Full Legal Name of Natural Control
Person (which means a natural person who directly you indirectly alone or with
others has power to vote or dispose of the securities covered by the
questionnaire):

 

 

 

2. 
Address for Notices to Selling Securityholder:

 

	
   

  
	
   

  
	
   

  
	
   Telephone:

  
	
   Fax:

  
	
   Contact
  Person:

  

 

1

 

3. 
Beneficial Ownership of Registrable Securities:

 

(a)           Type
and Principal Amount of Registrable Securities beneficially owned:

 

 

 

 

 

4. 
Broker-Dealer Status:

 

(a)           Are
you a broker-dealer?

 

Yes   o  No   o

 

Note:      If yes, the SEC’s staff has indicated that
you should be identified as an underwriter in the Registration Statement.

 

(b)           Are
you an affiliate of a broker-dealer?

 

Yes   o  No   o

 

(c)           If you are an affiliate of a broker-dealer,
do you certify that you bought the Registrable Securities in the ordinary
course of business, and at the time of the purchase of the Registrable
Securities to be resold, you had no agreements or understandings, directly or
indirectly, with any person to distribute the Registrable Securities?

 

Yes   o  No   o

 

Note:      If no, the SEC’s staff has indicated that
you should be identified as an underwriter in the Registration Statement.

 

5. 
Beneficial Ownership of Other Securities of the Company Owned by the
Selling Securityholder.

 

Except as set forth below in this Item 5, the undersigned is
not the beneficial or registered owner of any securities of the Company other
than the Registrable Securities listed above in Item 3.

 

(a)           Type
and Amount of Other Securities beneficially owned by the Selling
Securityholder:

 

 

 

 

2

 

6. 
Relationships with the Company:

 

Except as set forth below, neither the undersigned nor any
of its affiliates, officers, directors or principal equity holders (owners of
5% of more of the equity securities of the undersigned) has held any position
or office or has had any other material relationship with the Company (or its
predecessors or affiliates) during the past three years.

 

State any exceptions here:

 

 

 

 

The undersigned agrees to
promptly notify the Company of any inaccuracies or changes in the information
provided herein that may occur subsequent to the date hereof and prior to the
Effective Date for the Registration Statement.

 

By signing below, the
undersigned consents to the disclosure of the information contained herein in
its answers to Items 1 through 6 and the inclusion of such information in the
Registration Statement and the related prospectus.  The undersigned understands that such information will be relied
upon by the Company in connection with the preparation or amendment of the
Registration Statement and the related prospectus.

 

IN WITNESS WHEREOF the
undersigned, by authority duly given, has caused this Notice and Questionnaire
to be executed and delivered either in person or by its duly authorized agent.

 

	
  Dated:

  	
   

  	
   

  	
  Beneficial Owner:

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  
							

 

3Exhibit 4.14

 

SECURITIES
PURCHASE AGREEMENT

 

THIS SECURITIES PURCHASE AGREEMENT
(the or this “Agreement”) dated as
of April 19, 2004 is entered into by and among IMCOR Pharmaceutical Co., a
Nevada corporation (the “Company”), and the purchasers identified on
the signature pages hereto (each a “Purchaser”
and collectively, the “Purchasers”).

 

WHEREAS, the
Company and the Purchasers are executing and delivering this Agreement in
reliance upon the exemption from securities registration afforded by the
provisions of Regulation D (“Regulation D”), as promulgated by the U.S.
Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as
amended (the “1933 Act”);

 

WHEREAS, the
Company issued to the Purchasers certain Revolving Convertible Senior Secured
Promissory Notes in an aggregate principal amount of $4,160,000 (the “Convertible Notes”) and Secured Promissory
Notes in an aggregate principal amount of $8,564,500 (the “Demand Notes” and collectively with the
Convertible Notes, the “Notes”);

 

WHEREAS,
the financing transaction pursuant to that certain Securities Purchase
Agreement dated as of April 19, 2004 by and among the Company and certain
purchasers signatory thereto for the purchase of Company Common Stock (defined
below) and warrants to acquire Common Stock (the “Financing Securities Purchase Agreement”) triggers the
conversion of the Convertible Notes by their terms the Company has requested
that the Purchasers convert their Demand Notes (including any accrued but
unpaid interest thereon) into shares of common stock of the Company, $0.001 par
value per share (the “Common Stock”),
all upon the terms and conditions set forth in this Agreement (the “Debt Conversion”); and

 

WHEREAS,
the Notes are secured by liens, pledges, security interests and other
encumbrances, including security agreements, patent and trademark security
agreements and UCC-1 financing statements (collectively, the “Security Documents”).

 

NOW, THEREFORE, in
consideration of the mutual promises and covenants contained in this Agreement,
and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, intending to be legally bound by the terms and
conditions of this Agreement, the parties hereto hereby agree as follows.

 

1.                                      Purchase and Sale of Conversion Shares.

 

1.1.         Offering.  Subject to the terms and conditions of this
Agreement, each Purchaser hereby severally agrees to: (a) convert all principal
and accrued but unpaid interest due on the Convertible Notes as of the
conversion date into Common Stock at $0.75 per share on or effective as of the
date of the Initial Closing (defined below); and (b) agrees to convert all
principal and accrued but unpaid interest due on the Demand Notes as of the
conversion date into Common Stock at $0.75 per share on or effective as of the
date of the Second Closing (defined below). 
The shares of Common Stock issuable upon conversion of the Notes are
collectively referred to as the “Conversion
Shares.”

 

1

 

2.             Delivery of the Conversion Shares at the Closings.

 

2.1.         Initial Closing. 
The initial closing (the “Initial Closing”) shall take place at the offices of Grippo & Elden LLC, 227 W.
Monroe Street, Chicago, Illinois  60606
on the second business day following the date on which the applicable
conditions set forth in Section 5.2 (excluding Section 5.2.7) and Section 6
shall have been satisfied or waived by the appropriate parties, or at such
other time, date and place as are mutually agreeable to the Company and the
Purchasers subscribing for a majority of the Conversion Shares.  At the Initial Closing:

 

(a)           Each
Purchaser shall deliver its Convertible Notes for cancellation and the Company
shall deliver to each Purchaser certificates representing the Conversion Shares
to which such Purchaser is entitled as a result of the conversion of the
Convertible Notes.

 

(b)           From
and after the Initial Closing, the Convertible Notes shall represent solely the
right to receive the Conversion Shares in accordance with this Agreement, and
no further obligations shall accrue or exist under the Convertible Notes.

 

(c)           If
a Purchaser has lost its Convertible Note(s) and is unable to deliver its
Convertible Note at the Initial Closing, it shall submit an affidavit of loss
and indemnity agreement so that the Convertible Note may be replaced and deemed
cancelled in accordance with the terms hereof. 
In the event that as a result of the Debt Conversion, fractions of
shares would be required to be issued, such fractional shares shall be rounded
up to the nearest whole share.

 

2.2.         Second Closing. 
The second closing (the “Second Closing”) shall
take place at the offices of Grippo & Elden LLC, 227 W. Monroe Street,
Chicago, Illinois  60606 on the second
business day following the date on which the applicable conditions set forth in
Section 5.2, including 5.2.7, and Section 6 shall have been satisfied or waived
by the appropriate parties.  At the
Second Closing:

 

(a)           Each
Purchaser shall deliver its Demand Notes for cancellation and the Company shall
deliver to each Purchaser certificates representing the Conversion Shares to
which such Purchaser is entitled as a result of the conversion of the Demand
Notes.

 

(b)           From
and after the Second Closing, the Demand Notes shall represent solely the right
to receive the Conversion Shares in accordance with this Agreement, and no
further obligations shall accrue or exist under the Demand Notes.  Upon delivery of the Conversion Shares to
the Purchasers, all liens, pledges, security interests and other encumbrances
under the Security Documents shall be terminated and released, and each
Purchaser shall execute and deliver to the Company termination statements,
releases of liens and similar interests and in all other reasonable respects
shall cooperate with the Company to effect such termination and release.

 

(c)           If
a Purchaser has lost its Demand Note(s) and is unable to deliver its Demand
Notes at the Initial Closing, it shall submit an affidavit of loss and
indemnity agreement so that the Demand Notes may be replaced and deemed
cancelled in accordance with the terms hereof. 
In the event that as a result of the Debt Conversion, fractions of
shares would be required to be issued, such fractional shares shall be rounded
up to the nearest whole share.

 

The Initial Closing and the Second Closing are collectively referred to
herein as the “Closings” and individually as a “Closing.”  The date on which the Closings occur are
referred to herein as a “Closing Date.”

 

2

 

2.3.         Termination.  If by the applicable dates set forth in Section 5.2.10 the
conditions set forth in Section 5.2 that apply to the applicable Closing shall
not have been fulfilled by the Company, then each Purchaser to receive
Conversion Shares at such Closing shall, at its election, be relieved of all of
its obligations under this Agreement as to such Closing without thereby waiving
any other right it may have by reason of such failure or such
non-fulfillment.  If by the applicable
date set forth in Section 6.5, any of the conditions set forth in Section 6 of
this Agreement that apply to the applicable Closing shall not have been
fulfilled by any Purchaser, the Company shall, at its election, be relieved of
all of its obligations to such Purchaser under this Agreement as to such
Closing without thereby waiving any other right it may have by reason of such
failure or such non-fulfillment.

 

3.             Representations
and Warranties of the Company.  Except
as disclosed in the SEC Filings (as defined below) and the Disclosure Schedule
attached hereto (which Disclosure Schedule makes explicit reference to, and
shall only modify, the particular Section containing the representation or
warranty as to which exception is taken), the Company hereby represents and warrants
to the Purchasers as follows:

 

3.1.         Organization; Amended Articles.  The Company is a corporation duly organized,
validly existing and in corporate good standing under the laws of the State of
Nevada and is qualified to do business as a foreign corporation in each
jurisdiction in which such qualification is required, except where the failure
to be so qualified would not have, either individually or in the aggregate, a
material adverse effect on the business, operations, financial condition,
assets, prospects, liabilities or contractual rights of the Company, whether
individually or taken as a whole (a “Material Adverse Effect”).  The Company has, or prior to each Closing
will have, duly authorized the sale and issuance, pursuant to the terms of this
Agreement an adequate number shares of its Common Stock authorized and
available for purchase hereunder, having the rights, restrictions, privileges
and preferences set forth in the Amended and Restated Certificate of
Incorporation (the “Amended Articles”).

 

3.2.         Corporate Power.  The Company has all required corporate power
and authority to own its property, to carry on its business as presently
conducted or contemplated, to enter into and perform this Agreement, the
Registration Rights Agreement by and among the Company and the Purchasers in
the form attached as Exhibit A (the “Registration
Rights Agreement”), the Voting Agreement (as defined in Section
5.1.5), and the other agreements, documents and instruments contemplated hereby
(collectively with this Agreement, the “Conversion
Documents”),
and to carry out the transactions contemplated hereby.  The copies of the Amended Articles and
Bylaws of the Company, as amended to date, which have been furnished by the
Company to counsel for the Purchasers, are correct and complete at the date
hereof.  The Company is not in violation
of any term of its Amended Articles or Bylaws, each as amended, or in violation
of any term of any agreement, instrument, judgment, decree, order, statute,
rule or government regulation applicable to the Company or to which the Company
is a party, where any violation, noncompliance or default would result in a
Material Adverse Effect.

 

3.3.         Authorization.  The Conversion Documents are valid and
binding obligations of the Company, enforceable in accordance with their
terms.  The execution, delivery and
performance of the Conversion Documents have been duly authorized by all
necessary corporate or other action of the Company.  Subject to obtaining stockholder approval for the issuance of more
than 20% of the Company’s Common Stock pursuant to Nasdaq Marketplace Rule 4350
with respect to Conversion Shares to be issued at the Second Closing, the
issuance, sale and delivery of the Conversion Shares in accordance with this
Agreement have been, or will be prior to each Closing, duly authorized by all
necessary corporate action on the part of the Company.  The Conversion Shares when so issued, sold
and delivered against payment therefor in accordance with the provisions of
this Agreement will be duly and

 

3

 

validly issued, fully
paid and non-assessable.  No consent,
approval or authorization of, or designation, declaration or filing with, any
governmental authority or any other person or entity is required of the Company
in connection with the execution and delivery of the Conversion Documents, or
the issuance, sale and delivery of the Conversion Shares in accordance with the
terms of this Agreement, or the consummation of any other transaction contemplated
hereby or by the other Conversion Documents, except (i) the filing with the SEC
of one or more Registration Statements in accordance with the requirements
Registration Rights Agreement and the filing of a Form D with the SEC, (ii) any
filings required by state securities laws, (iii) the filings required in
accordance with Section 8.12, (iv) the filing of the Proxy Statement in
accordance with Section 5.1.4, and (v) those that have been made or obtained
prior to or as of the date of this Agreement.

 

3.4.         Capitalization.  The authorized capital stock of the Company
consists of Series A Preferred Stock, $0.001 par value per share, of which
12,856 shares are authorized, issued and outstanding as of December 31, 2003,
and 150,000,000 shares of Common Stock, $0.001 par value per share, of which
21,541,476 shares are issued and outstanding as of March 31, 2004.  All of the issued and outstanding shares of
the Company’s capital stock have been duly authorized and validly issued and
are fully paid and non-assessable.  The
Company will have reserved, immediately prior to the First Closing, a total of
6,068,740 shares of its Common Stock for issuance pursuant to the Option Plans
(defined below).  Except as contemplated
by this Agreement, the other Conversion Documents, the Amended Articles,
(i) no subscription, warrant, option, convertible security or other right
(contingent or otherwise) to purchase or acquire any shares of capital stock of
the Company is authorized or outstanding, (ii) there is not any commitment
or offer of the Company to issue any subscription, warrant, option, convertible
security or other such right or to issue or distribute to holders of any shares
of its capital stock any evidences of indebtedness or assets of the Company,
(iii) the Company has no obligation (contingent or otherwise) to purchase,
redeem or otherwise acquire any shares of its capital stock or any interest
therein or to pay any dividend or make any other distribution in respect
thereof, and (iv) there are no restrictions on the transfer of the Company’s
capital stock other than those arising from securities laws or contemplated by
this Agreement and the other Conversion Documents.  Except as contemplated by this Agreement and the other Conversion
Documents, there are no voting trusts or agreements, stockholders’ agreements,
pledge agreements, buy-sell agreements, rights of first refusal, preemptive
rights or proxies relating to any securities of the Company to which the
Company is a party.  All of the
outstanding securities of the Company were issued in compliance with all
applicable federal and state securities laws. 
Set forth in the Disclosure Schedule is a capitalization table for the
Company showing (i) the capitalization of the Company on a fully diluted
basis immediately prior to the issuance of the Conversion Shares; and
(ii) the capitalization of the Company on a fully diluted basis giving
effect to the issuance of the Conversion Shares and the shares to be issued
pursuant to the Financing Securities Purchase Agreement.  For the purposes of this Agreement, the term
“on a fully diluted basis” means that for purposes of calculating the
percentage interest of the Company’s capital stock represented by a specified
number of shares, there shall be deemed outstanding (i) all shares of Common
Stock, $0.001 per value per share, of the Company currently outstanding; (ii)
all shares of Common Stock issuable pursuant to the exercise of options granted
and capable of being granted under the Company’s 1998 Long Term Incentive
Compensation Plan, 2000 Long Term Incentive Compensation Plan, and Senior
Executive Long Term Incentive Compensation Plan (the “Option Plans”); and (iii) all
shares of Common Stock issuable pursuant to other existing options, warrants,
convertible debt securities and other instruments and agreements
whatsoever.  The issue and sale of the
Conversion Shares will not, immediately or with the passage of time, obligate
the Company to issue shares of Common Stock or other securities to any Person
and will not result in a right of any holder of Company securities to adjust
the exercise, conversion, exchange or reset price under such securities.

 

4

 

3.5.         Subsidiaries.  Except for Sentigen Ltd., the Company does not
control, directly or indirectly, any other entity (a “Subsidiary”) and does not own
of record or beneficially, directly or indirectly, any shares of capital stock
or securities convertible into capital stock of any other corporation, or any
participating interest in any partnership, joint venture or other non-corporate
business enterprise.

 

3.6.         SEC Filings; Business.  The Company has filed all reports required
to be filed by it under the 1933 Act and the Securities Exchange Act of 1934,
as amended (the “1934 Act”), including pursuant to Section 13(a) or 15(d)
thereof, for the twelve months preceding the date hereof (or such shorter
period as the Company was required by law to file such reports) (collectively,
the “SEC
Filings”) on a timely basis or has timely filed a valid extension of
such time of filing and any such SEC Filings have been accepted by the SEC
prior to the expiration of any such extension. 
The SEC Filings are the only filings required of the Company pursuant to
the 1934 Act for such period.  At the
time of filing thereof, the SEC Filings complied as to form in all material
respects with the requirements of the 1934 Act and did not contain any untrue
statement of a material fact or omit to state any material fact necessary in
order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. 
During the preceding two years, each registration statement and any
amendment thereto filed by the Company pursuant to the 1933 Act and the rules
and regulations thereunder, as of the date such statement or amendment became
effective, complied as to form in all material respects with the 1933 Act and
did not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements made therein, in light of the circumstances under which they were
made, not misleading; and each prospectus filed pursuant to Rule 424(b) under
the 1933 Act, as of its issue date and as of the closing of any sale of
securities pursuant thereto did not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading.  The Company and its Subsidiaries are engaged
only in the business described in the SEC Filings and the SEC Filings contain a
complete and accurate description in all material respects of the business of
the Company and its Subsidiaries, taken as a whole, as required to be
disclosed.

 

3.7.         No Material Adverse Change.  Since December 31, 2002, except as
identified and described in the SEC Filings, there has not been:

 

(a)           any change in the consolidated
assets, liabilities, financial condition or operating results of the Company
from that reflected in the financial statements included in the 2002 10-K,
except for changes in the ordinary course of business which have not and could
not reasonably be expected to have a Material Adverse Effect, individually or
in the aggregate;

 

(b)           any declaration or payment of any
dividend, or any authorization or payment of any distribution, on any of the
capital stock of the Company, or any redemption or repurchase of any securities
of the Company;

 

(c)           any material damage, destruction or
loss, whether or not covered by insurance to any assets or properties of the
Company;

 

(d)           any waiver, not in the ordinary
course of business, by the Company or any Subsidiary of a material right or of
a material debt owed to it;

 

(e)           any satisfaction or discharge of any
lien, claim or encumbrance or payment of any obligation by the Company or a
Subsidiary, except in the ordinary course of business and which is

 

5

 

not material to the
assets, properties, financial condition, operating results or business of the
Company and its Subsidiaries taken as a whole (as such business is presently
conducted and as it is proposed to be conducted);

 

(f)            any change or amendment to the
Company’s Amended Articles or Bylaws, or material change to any material
contract or arrangement by which the Company or any Subsidiary is bound or to
which any of their respective assets or properties is subject;

 

(g)           any material labor difficulties or
labor union organizing activities with respect to employees of the Company or
any Subsidiary;

 

(h)           any transaction entered into by the
Company or a Subsidiary other than in the ordinary course of business;

 

(i)            any loss of the services of any key
employee, or material change in the composition or duties of the senior
management of the Company or any Subsidiary;

 

(j)            any loss or threatened loss of any
customer which has had or could reasonably be expected to have a Material
Adverse Effect; or

 

(k)           any other event or condition of any
character that has had or could reasonably be expected to have a Material
Adverse Effect.

 

3.8.         Financial Statements.  The financial statements included in each
SEC Filing present fairly, in all material respects, the consolidated financial
position of the Company as of the dates shown and its consolidated results of
operations and cash flows for the periods shown, and such financial statements
have been prepared in conformity with United States generally accepted accounting
principles applied on a consistent basis (except as may be disclosed therein or
in the notes thereto, and, in the case of quarterly financial statements, as
permitted by Form 10-Q or Form 10-QSB, as applicable, under the 1934 Act).  Except as set forth in the financial
statements of the Company included in the SEC Filings filed prior to the date
hereof, neither the Company nor any of its Subsidiaries has incurred any
liabilities, contingent or otherwise, except those incurred in the ordinary
course of business, consistent (as to amount and nature) with past practices
since the date of such financial statements, none of which, individually or in
the aggregate, have had or could reasonably be expected to have a Material
Adverse Effect.

 

3.9.         Contracts and Commitments.  Except as identified and described in the SEC
Filings, the Company (i) is not a party to any oral or written contract,
obligation, instrument, corporate restriction or commitment which involves a
potential obligation or liability in excess of $25,000 and which is otherwise
material and not entered into in the ordinary course of business, (ii) does not
have any oral or written employment contracts, financing agreements, licenses,
distributor or sales representative agreements, agreements with officers,
directors, employees or shareholders of the Company or persons or organizations
related to or affiliated with any such persons, leases, agreements relating to
product development; and (iii) does not have any pension, profit sharing,
retirement or stock option plans other than the Option Plans and the Company’s
401(k) Plan.

 

6

 

3.10.       Proprietary Rights, Employee
Restrictions.

 

(a)           The Company owns or has the right to
use all copyrights, copyright registrations and copyright applications,
trademark registrations and applications for registration, patents and patent
applications, trademarks, service marks, trade names, or other proprietary
rights (collectively, “Intellectual Property Rights”) as described
in the SEC Filings used or useful in the Company’s business as presently
conducted or currently contemplated to be conducted and all licenses,
assignments and releases of Intellectual Property Rights of others in material
works embodied in the Company’s products. 
All Intellectual Property Rights held by any employee, officer or
consultant have been assigned to the Company. 
The Company has exclusive ownership of, or exclusive license to use, all
Intellectual Property Rights.  The
Company has obtained any licenses, releases or assignments necessary to use all
third parties’ Intellectual Property Rights in works embodied in its
products.  All such licenses, releases
and assignments are specifically identified in the Disclosure Schedule.  To the Company’s knowledge, neither the
present nor currently contemplated business activities or products of the
Company infringe any Intellectual Property Rights of others.  The Company has not received any notice or
other written claim from any person asserting that any of the Company’s present
or currently contemplated activities infringe or may infringe any Intellectual
Property Rights of such person.  The
Company has the right to use, free and clear of known or asserted claims or rights
of others, all trade secrets, customer lists, hardware designs, programming
processes, software and other information required for or incident to its
products or its business as presently conducted or contemplated to be
conducted, except for claims which would not have a Material Adverse Effect.  The Company has taken all reasonable
measures to protect and preserve the security, confidentiality and value of its
Intellectual Property Rights, including its trade secrets and other
confidential information.  The Company
is not aware of any infringement by others of its copyrights or other
Intellectual Proprietary Rights in any of its products, technology or services,
or any violation of the confidentiality of any of its proprietary
information.  The activities of the
Company’s employees on behalf of the Company do not violate any agreements or
arrangements known to the Company which any such employees have with former
employers or any other entity to whom such employees may have rendered
consulting services.  For the purposes
of this Section 3.10, Intellectual Property Rights also includes any and
all material licenses, databases, computer programs and other computer software
user interfaces (other than those generally available to the public), know-how,
trade secrets, customer lists, proprietary technology, processes and formulae,
source code, object code, algorithms, architecture, structure, display screens,
layouts, development tools, instructions, templates, marketing materials,
inventions, trade dress, logos and designs and all documentation and media
constituting, describing or relating to the foregoing.

 

(b)           All key employees, including all
consultants (contract or otherwise), of or to the Company have executed and
delivered to and in favor of the Company an agreement regarding the protection of
confidential and proprietary information and the assignment to the Company of
all Intellectual Property Rights arising from the services performed for the
Company by such Persons.

 

3.11.       Litigation; Compliance with Law.  There is no
(i) action, suit, claim, proceeding or investigation pending or, to the
best of the Company’s knowledge, threatened against or affecting the Company,
at law or in equity, or before or by any federal, state, municipal or other
governmental department, commission, board, bureau, agency or instrumentality,
domestic or foreign, (ii) arbitration or mediation proceeding relating to the
Company, pending or, to the best of the Company’s knowledge, threatened, or
(iii) governmental inquiry pending or, to the best of the Company’s knowledge,
threatened against or affecting the Company (including without limitation any
inquiry as to the qualification of the Company to hold or receive any license
or permit).  The Company has not
received any opinion or memorandum or legal advice from legal counsel to the
effect that it is exposed, from a legal standpoint,

 

7

 

to any liability which
may have a Material Adverse Effect.  The
Company is not in default with respect to any order, writ, injunction or decree
known to or served upon the Company of any court or of any federal, state,
municipal or other governmental department, commission, board, bureau, agency
or instrumentality, domestic or foreign. 
There is no action or suit by the Company, and to the best of the
Company’s knowledge, pending, threatened or contemplated against others.  To the best of the Company’s knowledge, the
Company has complied and will continue to comply, in all material respects,
with all laws, rules, regulations and orders applicable to its present and
contemplated business, operations, properties, assets, products and
services.  The Company has all necessary
permits, licenses and other authorizations required to conduct its business as conducted
and as proposed to be conducted, except where the failure to obtain such
permits, licenses or authorization would not have a Material Adverse Effect,
and the Company has been and will continue to be operating its business
pursuant to and in compliance with the terms of all such permits, licenses and
other authorizations, except where the failure to so operate the business would
not have a Material Adverse Effect.  The
Company has all franchises, permits, licenses and other rights and privileges
necessary to permit it to own its property and to conduct its business as it is
presently conducted or proposed to be conducted.  The Company is not subject to any pending or threatened
investigation, inquiry or proceeding by the SEC, any state securities commission
or any other federal, state, municipal or other governmental department,
commission, board, bureau, agency or instrumentality, domestic or foreign, or
any securities exchange or securities market, with respect to any matter.  The Company is in compliance with all
effective requirements of the Sarbanes-Oxley Act of 2002, as amended, and the
rules and regulations thereunder, that are applicable to it, except where such
noncompliance could not have or reasonably be expected to result in a Material
Adverse Effect.

 

3.12.       Leasehold Interests.  Each lease or agreement to which the Company
is a party under which it is a lessee of any property, real or personal,
is a valid and subsisting agreement, duly authorized and entered into, without
any default of the Company thereunder and, to the best of the Company’s
knowledge, without any default thereunder of any other party thereto.  No event has occurred and is continuing
which, with due notice or lapse of time or both, would constitute a default or
event of default by the Company under any such lease or agreement or, to the
best of the Company’s knowledge, by any other party thereto.  The Company’s possession of such property
has not been disturbed and, to the best of the Company’s knowledge, no claim
has been asserted against the Company adverse to its rights in such leasehold
interests.

 

3.13.       Insurance.  The Company and each Subsidiary maintain in
full force and effect insurance coverage that is customary for comparably
situated companies for the business being conducted and properties owned or
leased by the Company and each Subsidiary, and the Company reasonably believes
such insurance coverage to be adequate against all liabilities, claims and
risks against which it is customary for comparably situated companies to
insure.

 

3.14.       Loans and Advances.  The Company does not have any outstanding
loans or advances to any person and is not obligated to make any such loans or
advances.

 

3.15.       Assumptions, Guaranties, Etc. of
Indebtedness of Other Persons.  The Company has not assumed, guaranteed, endorsed or otherwise
become directly or contingently liable on any indebtedness of any other person
(including, without limitation, liability by way of agreement, contingent or
otherwise, to purchase, to provide funds for payment, to supply funds to or
otherwise invest in the debtor, or otherwise to assure the creditor against
loss), except for guaranties by endorsement of negotiable instruments for
deposit or collection in the ordinary course of business.

 

8

 

3.16.       Governmental Approvals.  Subject to the accuracy of the
representations and warranties of the Purchasers set forth in Section 4, no
registration or filing with, or consent or approval of or other action by, any
federal, state or other governmental agency or instrumentality is or will be
necessary for the valid execution, delivery and performance by the Company of
any of the Conversion Documents, the issuance, sale and delivery of the
Conversion Shares other than filings pursuant to federal and state securities
laws (all of which filings have been made by the Company, other than those
which are required to be made after the Closing and which will be duly made on
a timely basis) in connection with the sale of the Conversion Shares.

 

3.17.       Tax Matters.  Each of the Company and each Subsidiary has
timely prepared and filed all tax returns required to have been filed by the
Company or such Subsidiary with all appropriate governmental agencies and
timely paid all taxes shown thereon or otherwise owed by it.  The charges, accruals and reserves on the
books of the Company in respect of taxes for all fiscal periods are adequate in
all material respects, and there are no material unpaid assessments against the
Company or any Subsidiary nor any basis for the assessment of any additional
taxes, penalties or interest for any fiscal period or audits by any federal,
state or local taxing authority except for any assessment which is not material
to the Company and its Subsidiaries, taken as a whole.  All taxes and other assessments and levies
that the Company or any Subsidiary is required to withhold or to collect for
payment have been duly withheld and collected and paid to the proper
governmental entity or third party when due. 
There are no tax liens or claims pending or threatened against the
Company or any Subsidiary or any of their respective assets or property.  There are no outstanding tax sharing
agreements or other such arrangements between the Company and any Subsidiary or
other corporation or entity.

 

3.18.       Title to Properties.  The Company and each Subsidiary has good and
marketable title to all real properties and all other properties and assets
owned by it, in each case free and clear from any and all liens, security
interests, encumbrances and defects, and the Company and each Subsidiary holds
any leased real or personal property under valid and enforceable leases with no
exceptions that would materially interfere with the use made or currently
planned to be made thereof by them.

 

3.19.       No Labor Disputes.  No material labor dispute with the employees
of the Company or any Subsidiary exists or is imminent.

 

3.20.       Environmental Matters.  Neither the Company nor any Subsidiary is in
violation of any statute, rule, regulation, decision or order of any
governmental agency or body or any court, domestic or foreign, relating to the
use, disposal or release of hazardous or toxic substances or relating to the
protection or restoration of the environment or human exposure to hazardous or
toxic substances (collectively, “Environmental Laws”), owns or operates any
real property contaminated with any substance that is subject to any
Environmental Laws, is liable for any off-site disposal or contamination
pursuant to any Environmental Laws, and is subject to any claim relating to any
Environmental Laws, which violation, contamination, liability or claim has had
or could reasonably be expected to have a Material Adverse Effect, individually
or in the aggregate; and there is no pending or threatened investigation that
might lead to such a claim.

 

3.21.       Compliance with Nasdaq Continued Listing
Requirements.  The
Company is in compliance with applicable Nasdaq SmallCap Market continued
listing requirements.  There are no
proceedings pending or threatened against the Company relating to the continued
listing of the Company’s Common Stock on the Nasdaq SmallCap Market and the
Company has not received any notice of, nor is there any basis for, the
delisting of the Common Stock from the Nasdaq SmallCap Market.

 

9

 

3.22.       Brokers. 
The Company has no contract, arrangement or
understanding with any broker, finder or similar agent with respect to the
transactions contemplated by this Agreement.  
No person or entity will have, as a result of the transactions
contemplated by this Agreement, any right, interest or claim against or upon
the Company, any Subsidiary or a Purchaser for any commission, fee or other
compensation pursuant to any agreement, arrangement or understanding entered
into by or on behalf of the Company.

 

3.23.       Certain Registration Matters.  Assuming the accuracy of
the Purchasers’ representations and warranties set forth in Section 4.1-4.5, no
registration under the Securities Act is required for the offer and sale of the
Conversion Shares by the Company to the Purchaser under the Conversion
Documents.  The Company has not granted
or agreed to grant to any Person any rights (including “piggy-back”
registration rights) to have any securities of the Company registered with the
SEC or any other governmental authority that have not been satisfied or
deferred during the period between the date hereof and the date the Company’s
registration statement pursuant to the Registration Rights Agreement is
declared effective.  Other than the
Registration Statement (as defined in the Registration Rights Agreement), the
registration statement being filed pursuant to the terms of the Financing
Securities Purchase Agreement and that certain registration statement which may
be filed on behalf of Xmark Funds, Ltd. and Xmark Funds, L.P., prior to the
date that a Registration Statement is first declared effective by the SEC, the
Company may not file any registration statement (other than on Form S-8) with
the SEC with respect to any securities of the Company.

 

3.24.       Transactions With Affiliates.  Except as identified and described in the
SEC Filings, no director, officer, employee or stockholder of the Company, or
member of the family of any such person, or any corporation, partnership, trust
or other entity in which any such person, or any member of the family of any
such person, has a substantial interest or is an officer, director, trustee,
partner or holder of more than 5% of the outstanding capital stock thereof, is
a party to any transaction with the Company, including any contract, agreement
or other arrangement providing for the employment of, furnishing of services
by, rental of real or personal property from or otherwise requiring payments to
any such person or firm, other than employment-at-will arrangements in the
ordinary course of business.

 

3.25.       Questionable Payments.  Neither the Company nor any of its
Subsidiaries nor any of their respective current or former shareholders,
directors, officers, employees, agents or other persons or entities acting on
behalf of the Company or any Subsidiary, has on behalf of the Company or any
Subsidiary or in connection with their respective businesses: (a) used any
corporate funds for unlawful contributions, gifts, entertainment or other
unlawful expenses relating to political activity; (b) made any direct or
indirect unlawful payments to any governmental officials or employees from
corporate funds; (c) established or maintained any unlawful or unrecorded fund
of corporate monies or other assets; (d) made any false or fictitious entries
on the books and records of the Company or any Subsidiary; or (e) made any
unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful
payment of any nature.

 

3.26.       Information Supplied to Purchasers.  Neither this Agreement, the Disclosure
Schedule and Exhibits attached hereto, nor any other Conversion Documents
furnished to the Purchasers by or on behalf of the Company contains any untrue
statement of a material fact, and none of this Agreement, the Disclosure Schedule
and Exhibits attached hereto, or such other Conversion Documents omits to state
a material fact necessary in order to make the statements contained herein or
therein not misleading.  None of the
matters described on the Disclosure Schedules have had, or could reasonably be
expected to have, a Material Adverse Effect, individually or in the aggregate.

 

10

 

3.27.       Internal Accounting Controls.  The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with
management’s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with
generally accepted accounting principles and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for
assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences.  The Company has established disclosure
controls and procedures (as defined in 1934 Act Rules 13a-14 and 15d-14) for
the Company and designed such disclosure controls and procedures to ensure that
material information relating to the Company, including its Subsidiaries, is
made known to the certifying officers by others within those entities,
particularly during the period in which the Company’s Form 10-KSB or 10-QSB, as
the case may be, is being prepared.

 

3.28.         No Additional Agreements.  The Company does not have any
agreement or understanding with any Purchaser with respect to the transactions
contemplated by the Conversion Documents other than as specified in the
Conversion Documents.

 

3.29.         Disclosure.  The Company confirms that neither it nor any person acting
on its behalf has provided any Purchaser or its respective agents or counsel
with any information that the Company believes constitutes material, non-public
information except insofar as the existence and terms of the proposed
transactions hereunder may constitute such information. The Company understands
and confirms that the Purchasers will rely on the foregoing representations and
covenants in effecting transactions in securities of the Company.

 

4.             Representations
of the Purchasers. 
Each of the Purchasers represents and warrants to the Company as to
itself and no other Purchaser as follows:

 

4.1.         Validity.  Assuming the due execution and delivery by
the Company of this Agreement and the Conversion Documents, this Agreement and
the Conversion Documents to which such Purchaser is a party constitute legal,
valid and binding obligations of the Purchaser, enforceable against such
Purchaser in accordance with their respective terms.

 

4.2.         Investor Status.  Such Purchaser is an “accredited investor”
as such term is defined in Regulation D under the 1933 Act.  Such Investor is not a registered
broker-dealer under Section 15 of the 1934 Act.

 

4.3.         Investment.  The Conversion Shares to be received by such
Purchaser hereunder will be acquired for the Purchaser’s own account, not as
nominee or agent, and not with a view to the resale or distribution of any part
thereof in violation of the 1933 Act, and the Purchaser has no intention of
selling, granting any participation in, or otherwise distributing the same in
violation of the 1933 Act.  Such
Purchaser is acquiring the Conversion Shares hereunder in the ordinary course
of its business. Such Purchaser does not have any agreement or understanding,
directly or indirectly, with any Person to distribute any of the Conversion
Shares.

 

4.4.         Investment Experience.  Such Purchaser acknowledges that it can bear
the economic risk and complete loss of its investment in the Conversion Shares
and has such knowledge and experience in financial or business matters that it
is capable of evaluating the merits and risks of the investment contemplated
hereby.

 

11

 

4.5.         Restricted Securities.  Such Purchaser understands that the
Conversion Shares are characterized as “restricted securities” under the U.S.
federal securities laws inasmuch as they are being acquired from the Company in
a transaction not involving a public offering and that under such laws and
applicable regulations such securities may be resold without registration under
the 1933 Act only in certain limited circumstances.

 

4.6.         Access to Management.  Such Purchaser has had an opportunity to
receive additional information related to the Company requested by it and to
ask questions of and receive answers from the Company regarding the Company,
its business and the terms and conditions of the offering of the Conversion
Shares.  Neither such inquiries nor any
other investigation conducted by or on behalf of such Purchaser or its
representatives or counsel shall modify, amend or affect such Purchaser’s right
to rely on the truth, accuracy and completeness of the Company’s
representations and warranties contained in the Conversion Documents.

 

4.7.         No General Solicitation.  Such Purchaser did not learn of the
investment in the Conversion Shares as a result of any public advertising or
general solicitation.

 

4.8.         Independent Investment Decision.  Such Purchaser has independently
evaluated the merits of its decision to purchase Conversion Shares pursuant to
this Agreement, such decision has been independently made by such Purchaser and
such Purchaser confirms that it has only relied on the advice of its own business
and/or legal counsel (which such Purchaser acknowledges is not Bryan Cave LLP)
and not on the advice of any other Purchaser’s business or legal counsel nor
upon any investment banker, placement agent, or their respective counsel in
making such decision.

 

5.             Pre-Closing
Covenants; Conditions to the Obligations of the Purchasers.

 

5.1.         Pre-Closing Covenants.  The parties covenant and agree that they
will perform and observe the following covenants and provisions until the
Second Closing Date, as applicable.

 

5.1.1.                  Dealings with
Affiliates.  Except as contemplated
herein, the Company will not enter into any transaction, including, without
limitation, any loans, leases, extension of credit or royalty agreements with
any employee, officer or director of the Company  or holder of ten percent (10%) or more of any class of
capital stock of the Company, or any member of their respective immediate
families or any corporation or other entity directly or indirectly controlled
by one or more of such employees, officers, directors or stockholders or
members of their immediate families.

 

5.1.2.                  Distributions.  Except as contemplated herein, the Company
will not declare or pay any dividends, purchase, redeem, retire, or otherwise
acquire for value any of its capital stock (or rights, options or warrants to
purchase such shares) now or hereafter outstanding, return any capital to its
stockholders as such, or make any distribution of assets to its stockholders as
such, or pay into or set aside a sinking fund for such purpose (such
transactions being hereinafter referred to as “Distributions”); provided,
however, that nothing herein contained shall prevent the Company from:

 

(i)            complying with any specific
provision of the terms of this Agreement;

 

(ii)           redeeming any stock of a deceased
stockholder out of insurance held by the Company on that stockholder’s life; or

 

12

 

(iii)          repurchasing any stock of an officer,
employee or consultant subject to a stock repurchase agreement under which the
Company has the right or obligation to repurchase such shares in the event of
termination of employment or of a consulting arrangement.

 

5.1.3.                  Extraordinary
Corporate Transactions.  Except as
contemplated herein, the Company will not take any corporate action, enter into
any agreement to take such action, or obligate itself to take any such action,
if such action would:

 

(i)            cause the Company to create,
authorize or issue any class or series of capital stock with equity features or
convertible into equity ranking senior to the Common Stock with respect to
liquidation preferences, dilution protection, redemption rights, or payment of
dividends, or otherwise having terms and conditions superior to the terms of
the Common Stock, or that would impair or limit the Company’s obligations under
this Agreement;

 

(ii)           enter into any transaction that
expressly prohibits or limits the Company’s right to perform its obligations
under this Agreement;

 

(iii)          cause or authorize any transaction,
whether by consolidation or merger of the Company, which results in the holders
of the Company’s capital stock holding less than 50% of the voting securities
of the resulting or surviving entity, or a sale of all or substantially all of
the capital stock or assets of the Company, or any other form of business
combination or acquisition in which the Company is the object of the
acquisition and in which control of the voting securities or assets of the
Corporation are transferred in any way;

 

(iv)          create or incur any additional
indebtedness (other than replacement of existing indebtedness for borrowed
money) for money borrowed which is secured by assets of the Company or any
subsidiary or otherwise mortgage or pledge, or create a security interest in
all or substantially all of the property of the Company;

 

(v)           change the principal business of the
Company, enter new lines of business, or exit its current and proposed line of
business;

 

(vi)          make investments in, or loans to, any
third parties other than for employee travel or relocation; or

 

(vii)         make any single capital expenditure in
excess of $50,000.

 

5.1.4.      Proxy Statement.  The Company shall (a) prepare and file with
the SEC, promptly after the date hereof and in any event by the 10th
business day following the Initial Closing, preliminary proxy materials with
respect to a meeting of the Company’s stockholders for the purpose of approving
the issuance of the Conversion Shares to be issued at the Second Closing, as
contemplated by this Agreement. 
Promptly after comments are received from the SEC with respect to the
preliminary proxy materials and after the furnishing by the Company of all
information required to be contained therein, the Company shall file with the
SEC the definitive proxy statement and (b) acting through the Company’s Board
of Directors, (i)  call a meeting of the
holders of the Common Stock for the purpose of approving the issuance of the
Conversion Shares to be issued at the Second Closing as contemplated by this Agreement
and (ii) include in the proxy statement the recommendation of its Board of
Directors that holders of the Common Stock approve such issuance as
contemplated by this Agreement.

 

13

 

5.1.5.      Stockholders
Agreement.  The Company shall
obtain on or before the date of the Initial Closing, a duly executed and
delivered Voting Agreement (the “Voting Agreement”) among the holders of at least 50%
of the Common Stock to approve the issuance of the Conversion Shares at the
Second Closing as contemplated by this Agreement.

 

5.2.         Conditions to the Obligations of the
Purchasers.  The
obligations of the Purchasers under this Agreement are subject to the
fulfillment, or the waiver by the Purchasers, of the conditions set forth in
this Section 5.2 on or before each Closing Date. All such documents and actions
shall be satisfactory in form and substance to such Purchaser and its counsel.

 

5.2.1.      Accuracy of Representations and
Warranties; Performance. 
Each representation and warranty of the Company contained in this
Agreement shall be true and correct in all material respects on and as of each
Closing Date, with the same effect as though such representation and warranty
had been made on and as of that date. 
The Company shall have performed in all material respects all agreements
and covenants required to be performed by it under the Conversion Documents
prior to such Closing Date.

 

5.2.2.      Consents.  The Company shall have obtained any and all
consents, permits, approvals, registrations and waivers necessary or appropriate
for consummation of the purchase and sale of the Conversion Shares to be
offered and sold at such Closing.  No
judgment, writ, order, injunction, award or decree of or by any court, or
judge, justice or magistrate, including any bankruptcy court or judge, or any
order of or by any governmental authority, shall have been issued, and no
action or proceeding shall have been instituted by any governmental authority,
enjoining or preventing the consummation of the transactions contemplated
hereby or in the other Conversion Documents.

 

5.2.3.      Certificates and Documents.  The Company shall have delivered to counsel
to the Purchasers:

 

(a)           the Amended Articles, certified by
the Secretary of State of the State of Nevada;

 

(b)           a certificate, as of the most recent
practicable date, of the Secretary of State of the State of Nevada as to the
Company’s legal existence and corporate good standing;

 

(c)           the Bylaws of the Company in effect
on and as of the First Closing Date; and

 

5.2.4.      Opinion.  The Company shall have delivered to counsel
to the Purchasers an original opinion from Grippo & Elden LLC, counsel to
the Company, dated as of the Closing Date, addressed to the Purchasers, and in
the form attached hereto as Exhibit B.

 

5.2.5.      SEC Approvals; Effective Registration;
Blue Sky.  Any SEC
approval required to consummate the transactions contemplated by the Conversion
Documents (other than the effectiveness of registration statements) shall have
been obtained.

 

5.2.6.      Registration Rights Agreement.  The Company shall have executed and
delivered to the Purchasers the Registration Rights Agreement.

 

5.2.7.      Stockholder Approval.  With respect to the Second Closing, on or
before July 19, 2004 the Company’s stockholders shall have approved the
issuance of the Conversion Shares at the Second Closing, as contemplated by
this Agreement, the conversion of the Demand Notes issued to

 

14

 

three
Company stockholders (Oxford Bioscience Partners IV L.P., Mi3 L.P. and MRNA
Fund II L.P.) into Common Stock at $0.75 per share and the issuance of shares
of the Company’s Common Stock and warrants to purchase shares of the Company’s
Common Stock in accordance with the Financing Securities Purchase Agreement.

 

5.2.8.      Nasdaq Listing.  The Nasdaq Stock Market shall have waived application of
the 15 day prior notice contained in NASD Marketplace Rule 4310(c)(17)(D) or
such timeframe shall have expired without objection.  Trading in the Common Stock shall not have been suspended by the
SEC or the Nasdaq Stock Market (except for any suspensions of trading of not
more than one trading day solely to permit dissemination of material
information regarding the Company) at any time since the date of execution of
this Agreement, and the Common Stock shall have been at all times since such
date listed for trading on the Nasdaq Small Cap Market or Nasdaq National
Market.

 

5.2.9.      No Adverse Changes.  Between the execution of this
Agreement and such Closing, no event or series of events (other than stock price
fluctuations) shall have occurred which reasonably would be expected to have or
result in a material adverse effect on the results of operations, assets,
prospects, business or condition (financial or otherwise) of the Company and
the Subsidiaries, taken as a whole.

 

5.2.10.    Timing. 
The Initial Closing shall occur effective as of the date of the initial
closing under the terms of the Financing Securities Purchase Agreement.  The Second Closing shall occur effective as
of the date of the second closing under the terms of the Financing Securities
Purchase Agreement.

 

6.             Conditions
to the Obligations of the Company.  The obligations of the Company under this Agreement are subject
to the fulfillment, or the waiver in writing by the Company, of the conditions
set forth in this Section 6 on or before each Closing Date.

 

6.1.         Accuracy of Representations and
Warranties.  The
representations and warranties of the Purchasers contained in Section 4 shall
be true and correct in all material respects on and as of each Closing Date,
with the same effect as though such representations and warranties had been
made on and as of that date.

 

6.2.         Performance.  The Purchasers shall have performed and
complied with all agreements contained in this Agreement required to be performed
and complied with by it prior to or at the Closing.

 

6.3.         Stockholder Approval.  With respect to the Second Closing, the Company’s stockholders shall have approved
the issuance of the Conversion Shares at the Second Closing, as contemplated by
this Agreement.

 

6.4.         Nasdaq
Listing.  The Nasdaq Stock
Market shall have waived application of the 15 day prior notice contained in
NASD Marketplace Rule 4310(c)(17)(D) or such timeframe shall have expired
without objection.

 

6.5.         Timing.  The Initial Closing shall have occurred no later than April
19, 2004.  The Second Closing shall have
occurred no later than July 19, 2004.

 

15

 

7.             Post Closing Covenants.

 

7.1.         No Integration.  Neither the Company nor any of its
affiliates, nor any person or entity acting on its or their behalf will make
any offers or sales of any Company security or solicit any offers to buy any
security, under circumstances that would adversely affect reliance by the
Company on Section 4(2) of the 1933 Act for the exemption from registration for
the transactions contemplated hereby or would require registration of the
Conversion Shares under the 1933 Act.

 

7.2.         Non-Contravention.  The Company will not take any action, enter
into any agreement or make any commitment that would conflict or interfere with
the obligations to the Purchasers under the Conversion Documents.

 

7.3.         Listing of Conversion Shares.  The Company shall take such action as may be
required to cause the Conversion Shares to be listed on the Nasdaq SmallCap
Market no later than the date required under the rules and regulations
thereof.  Further, if the Company
applies to have its Common Stock or other securities traded on any other
principal stock exchange or market, it shall include the Conversion Shares in
such application and will take such other action as is necessary to cause such
Common Stock to be so listed.  The
Company will use reasonable best efforts to continue the listing and trading of
its Common Stock on The Nasdaq SmallCap Market or on the Nasdaq National Market
and, in accordance, therewith, will use its best efforts to comply in all
respects with the Company’s reporting, filing and other obligations under the
bylaws or rules of such exchange, as applicable.

 

7.4.         Non-Public Information.  The Company covenants and agrees
that neither it nor any other Person acting on its behalf will provide any
Purchaser or its agents or counsel with any information that the Company
believes constitutes material non-public information, unless prior thereto such
Purchaser shall have executed a written agreement regarding the confidentiality
and use of such information.  The
Company understands and confirms that each Purchaser shall be relying on the
foregoing representations in effecting transactions in securities of the
Company.

 

8.             General.

 

8.1.         Successors and Assigns.  The provisions of this Agreement shall bind
and inure to the benefit of the respective successors, assigns, heirs,
executors, and administrators of the parties hereto, including but not limited
to assigns of the Purchasers pursuant to Section 1.1 of this Agreement.

 

8.2.         Survival of Representations and
Warranties.  All
representations and warranties shall survive and remain in full force and
effect after the Closing with respect to the Company.

 

8.3.         Indemnification.  The Company agrees to indemnify and hold
harmless each Purchaser and its affiliates and their respective directors,
officers, employees and agents from and against any and all losses, claims,
damages, liabilities and expenses (including without limitation reasonable
attorney fees and disbursements and other expenses incurred in connection with
investigating, preparing or defending any action, claim or proceeding, pending
or threatened and the costs of enforcement hereof) to which such person or
entity may become subject as a result of and will reimburse any such person or
entity for all such amounts as they are incurred by such person or entity as a
result of any breach of representation, warranty, covenant or agreement made by
or to be performed on the part of the Company under the Conversion Documents.

 

16

 

8.4.         Conduct of Indemnification Proceedings.  Promptly after receipt by any person or
entity (the “Indemnified Person”) of notice of any demand, claim or
circumstances which would or might give rise to a claim or the commencement of
any action, proceeding or investigation by a third party in respect of which
indemnity may be sought pursuant to Section 8.3 hereof, such Indemnified Person
shall promptly notify the Company in writing and the Company shall assume the
defense thereof, including the employment of counsel reasonably satisfactory to
such Indemnified Person, and shall assume the payment of all fees and expenses;
provided, however, that the failure of any Indemnified Person so to notify the
Company shall not relieve the Company of its obligations hereunder except to
the extent that the Company is materially prejudiced by such failure to notify.  In any such proceeding, any Indemnified
Person shall have the right to retain its own counsel, but the fees and
expenses of such counsel shall be at the expense of such Indemnified Person
unless: (i) the Company and the Indemnified Person shall have mutually agreed
to the retention of such counsel; or (ii) in the reasonable judgment of counsel
to such Indemnified Person representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between
them.  The Company shall not be liable
for any settlement of any proceeding effected without its written consent,
which consent shall not be unreasonably withheld, but if settled with such
consent, or if there be a final judgment for the plaintiff, the Company shall
indemnify and hold harmless such Indemnified Person from and against any loss
or liability (to the extent stated above) by reason of such settlement or
judgment.  Without the prior written
consent of the Indemnified Person, which consent shall not be unreasonably withheld,
the Company shall not effect any settlement of any pending or threatened
proceeding in respect of which any Indemnified Person is or could have been a
party and indemnity could have been sought hereunder by such Indemnified Party,
unless such settlement includes an unconditional release of such Indemnified
Person from all liability arising out of such proceeding.

 

8.5.         Notices. All notices,
requests, consents and other communications under this Agreement shall be in
writing and shall be delivered by hand, by telecopier, by express overnight
courier service or mailed by first class mail, postage prepaid, to the
respective addresses set forth on the signature pages of this Agreement, as
such addresses may be modified by notice given pursuant to this Section 8.5,
with copies provided simultaneously to counsel as set forth on the signature
pages of this Agreement.  Notices
provided in accordance with this Section 8.5 shall be deemed delivered upon
personal delivery, receipt by telecopy or overnight mail, or 48 hours after
deposit in the mail in accordance with the above.

 

8.6.         Entire Agreement.  This Agreement, together with the
instruments and other documents hereby contemplated to be executed and
delivered in connection herewith, contains the entire agreement and
understanding of the parties hereto, and supersedes any prior agreements or
understandings between or among them, with respect to the subject matter
hereof.  Except as expressly set forth
in this Agreement, the Disclosure Schedule, the Exhibits attached hereto and
the Conversion Documents, the Company makes no representation or warranty,
express or implied, with respect to the transactions contemplated by this
Agreement or the other Conversion Documents, the business of the Company, the
Company, the Company’s assets or its future prospects.  No party is relying on any understandings,
agreements or representations other than those expressly contained this
Agreement, the Disclosure Schedule, the Exhibits attached hereto, the SEC
Filings and the Conversion Documents.

 

8.7.         Amendments
and Waivers.  No provision of this Agreement may be
waived or amended except in a written instrument signed by the Company and the
Purchasers holding a majority of the Conversion Shares.  No waiver of any default with respect to any
provision, condition or requirement of this Agreement shall be deemed to be a
continuing waiver in the future or a waiver of any subsequent default or a
waiver of any other provision, condition or requirement hereof, nor shall any
delay or omission of either party to exercise any right hereunder in any manner
impair the exercise of any such

 

17

 

right.  No consideration shall
be offered or paid to any Investor to amend or consent to a waiver or modification
of any provision of any Conversion Document unless the same consideration is
also offered to all Investors who then hold Shares.

 

8.8.         Counterparts.  This Agreement may be executed in several
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

8.9.         Captions.  The captions of the sections, subsections
and paragraphs of this Agreement have been added for convenience only and shall
not be deemed to be a part of this Agreement.

 

8.10.       Severability.  Each provision of this Agreement shall be
interpreted in such manner as to validate and give effect thereto to the
fullest lawful extent, but if any provision of this Agreement is determined by
a court of competent jurisdiction to be invalid or unenforceable under
applicable law, such provision shall be ineffective only to the extent so
determined and such invalidity or unenforceability shall not affect the
remainder of such provision or the remaining provisions of this Agreement.

 

8.11.       Governing Law.  This Agreement shall be governed by and
interpreted and construed in accordance with the laws of the State of New York;
provided, however, that matters relating to the authorization, issuance
and enforceability of the terms of the Conversion Shares shall be governed and
interpreted and construed in accordance with the Nevada General Corporation
Law.  The Company irrevocably submits to
the exclusive jurisdiction of the state and federal courts located in the State
of New York  for the purpose of any
suit, action, proceeding or judgment relating to or arising out of this
Agreement and the transactions contemplated hereby.  Service of process in connection with any such suit, action or
proceeding may be served on each party hereto anywhere in the world by the same
methods as are specified for the giving of notices under this Agreement.  The Company irrevocably consents to the
jurisdiction of any such court in any such suit, action or proceeding and to
the laying of venue in such court. The Company irrevocably waives any objection
to the laying of venue of any such suit, action or proceeding brought in such
courts and irrevocably waives any claim that any such suit, action or
proceeding brought in any such court has been brought in an inconvenient
forum.  If either party shall commence
an action to enforce any provisions of a Conversion Document, then the
prevailing party in such action shall be reimbursed by the other party for its
reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action.

 

8.12.       Independent Nature of Purchasers.  The obligations of each
Purchaser under any Conversion Document are several and not joint with the
obligations of any other Purchaser, and no Purchaser shall be responsible in
any way for the performance of the obligations of any other Purchaser under any
Conversion Document.  The decision of
each Purchaser to purchase Conversion Shares pursuant to the Conversion
Documents has been made by such Purchaser independently of any other
Purchaser.  Nothing contained herein or
in any Financing Document, and no action taken by any Purchaser pursuant
thereto, shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create a
presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the
Conversion Documents.  Each Purchaser
acknowledges that no other Purchaser has acted as agent for such Purchaser in
connection with making its investment hereunder and that no Purchaser will be
acting as agent of such Purchaser in connection with monitoring its investment
in the Conversion Shares or enforcing its rights under the Conversion
Documents.  Each Purchaser shall be
entitled to independently protect and enforce its rights, including without
limitation the rights arising out of this Agreement or out of the other Conversion
Documents, and it shall not be necessary for any other Purchaser to be joined
as an additional party in any proceeding for such purpose.  The Company acknowledges that each of the

 

18

 

Purchasers has been
provided with the same Conversion Documents for the purpose of closing a
transaction with multiple Purchasers and not because it was required or
requested to do so by any Purchaser.

 

8.13.       Securities Laws Disclosure;
Publicity.  By 9:00 a.m. (New York
time) on the business day following the execution of this Agreement, and by
9:00 a.m. (New York time) on each Closing Date, the Company shall issue press
releases disclosing the transactions contemplated hereby and each Closing.  On the business day following the execution
of this Agreement the Company will file a Current Report on Form 8-K disclosing
the material terms of the Conversion Documents (and attach as exhibits thereto
the Conversion Documents), and on each Closing Date the Company will file an
additional Current Report on Form 8-K to disclose such Closing.  In addition, the Company will make such
other filings and notices in the manner and time required by the SEC and the
Nasdaq Stock Market.  Notwithstanding the
foregoing, the Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the SEC (other than the
Registration Statements and any exhibits to filings made in respect of this
transaction in accordance with periodic filing requirements under the 1934 Act)
or any regulatory agency or the Nasdaq Stock Market, without the prior written
consent of such Purchaser, except to the extent such disclosure is required by
law or Nasdaq Stock Market regulations.

 

8.14.       Remedies.  In addition to being entitled to
exercise all rights provided herein or granted by law, including recovery of
damages, each of the Investors and the Company will be entitled to specific
performance under the Conversion Documents. 
The parties agree that monetary damages may not be adequate compensation
for any loss incurred by reason of any breach of obligations described in the
foregoing sentence and hereby agrees to waive in any action for specific
performance of any such obligation the defense that a remedy at law would be
adequate.

 

8.15.       Payment Set Aside.  To the extent that the Company
makes a payment or payments to any Purchaser pursuant to any Conversion
Document or a Purchaser enforces or exercises its rights thereunder, and such
payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or
preferential, set aside, recovered from, disgorged by or are required to be
refunded, repaid or otherwise restored to the Company, a trustee, receiver or
any other person under any law (including, without limitation, any bankruptcy
law, state or federal law, common law or equitable cause of action), then to
the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and
effect as if such payment had not been made or such enforcement or setoff had
not occurred.

 

8.16.       Limitation of Liability.  Notwithstanding anything herein to the
contrary, the Company acknowledges and agrees that the liability of a Purchaser
arising directly or indirectly, under any Conversion Document of any and every
nature whatsoever shall be satisfied solely out of the assets of such
Purchaser, and that no trustee, officer, other investment vehicle or any other
Affiliate of such Purchaser or any investor, shareholder or holder of shares of
beneficial interest of such a Purchaser shall be personally liable for any
liabilities of such Purchaser.

 

[Signature Pages Follow]

 

19

 

IN WITNESS WHEREOF,
the parties have executed this Securities Purchase Agreement as of the day and
year first above written.

 

	
   

  	
  IMCOR Pharmaceutical Co.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Taffy J. Williams,
  Ph.D., President

  	
   

  
	
   

  	
   

  
	
   

  	
  Notice Address:

  	
  6175 Lusk Boulevard

  	
   

  
	
   

  	
   

  	
  San Diego, CA  92121

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Purchasers:

  
	
   

  	
   

  
	
   

  	
  Mi3
  L.P.

  
	
   

  	
   

  
	
   

  	
  By:  MI3 Services L.L.C., its General Partner

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  William D. McPhee,
  President

  	
   

  
	
   

  	
   

  
	
   

  	
  Oxford
  Bioscience Partners IV L.P.

  
	
   

  	
   

  
	
   

  	
  By:  OBP Management IV L.P.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Jonathan J. Fleming,
  General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  MRNA
  Fund II L.P.

  
	
   

  	
   

  
	
   

  	
  By:  OBP Management IV L.P.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Jonathan J. Fleming,
  General Partner

  	
   

  
								

 

20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]